CM
OMED

Crestline Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Crestline Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-209,088
Closed -$483K – 281
2018
Q2 		$483K Buy
209,088
+8,134
+4% +$23.7K 0.05% 225
2018
Q1 		$639K Buy
200,954
+17,267
+9% +$47.6K 0.08% 181
2017
Q4 		$753K Buy
+183,687
New +$799K 0.08% 122

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Crestline Management's OMED Position: Q3 2018 in Review

Crestline Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 209,088 shares — an estimated $483K sold.

Crestline Management first reported a position in OMED in Q4 2017 and held it in 3 quarters. The position peaked at $753K in Q4 2017. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Crestline Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 209,088 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $483K.
  • Crestline Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Crestline Management's OncoMed Pharmaceuticals, Inc. position peaked at $753K in Q4 2017.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.